# EDGAR Filing Document

**Accession Number:** 0002011514
**File Stem:** 0001140361-25-039496
**Filing Date:** 2025-10
**Character Count:** 8433
**Document Hash:** efa149047fddc7d981d14a357eb40d33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-039496.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001140361-25-039496

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251027

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anteris Technologies Global Corp.
- **CENTRAL INDEX KEY:** 0002011514
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42437
- **FILM NUMBER:** 251420728

**BUSINESS ADDRESS:**
- **STREET 1:** 860 BLUE GENTIAN ROAD
- **STREET 2:** SUITE 340
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121
- **BUSINESS PHONE:** 651-493-0606

**MAIL ADDRESS:**
- **STREET 1:** 860 BLUE GENTIAN ROAD
- **STREET 2:** SUITE 340
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of The Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): October 27, 2025

------

## Anteris Technologies Global Corp.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **001-42437**<br>| **99-1407174**<br>|
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

---

| | |
|:---|:---|
| **Toowong Tower, Level 3, Suite 302**<br> **9 Sherwood Road**<br>**Toowong, QLD<br> Australia <br>** <br>| **4066**<br>|
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: +61 7 3152 3200

#### Not Applicable

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.0001 per share<br>| AVR<br>| The Nasdaq Global Market<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 3.02.** | **Unregistered Sales of Equity Securities.** |

---

The information contained in Item 8.01 below with respect to the Additional Securities (as defined below) is incorporated by reference in this Item 3.02.

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.** |

---

As previously disclosed, on October 23, 2025 (October 24, 2025 AEST), Anteris Technologies Global Corp. (the "Company") entered into (i) subscription agreements (the "Subscription Agreements") with certain investors, pursuant to which the Company agreed to sell 2,244,896 shares (the "Shares") of the Company's common stock, par value $0.0001 per share ("Common Stock"), and accompanying five-year warrants (the "Common Stock Warrants") to purchase 2,244,896 shares of Common Stock at a price of US$4.90 per share of Common Stock and accompanying Common Stock Warrant (the "Common Stock Offering"), and (ii) confirmation letters (the "Confirmation Letters") with certain investors, pursuant to which the Company agreed to sell 2,788,064 CHESS Depositary Interests ("CDIs") and accompanying five-year warrants (the "CDI Warrants") to purchase 2,788,064 CDIs at a price of A$7.50 per CDI and accompanying CDI Warrant (the "CDI Offering" and, together with the Common Stock Offering, the "Offering"). Each of the Common Stock Warrants and the CDI Warrants are exercisable commencing six months following the date of issuance.

On October 24, 2025, as part of the Common Stock Offering, the Company entered into Subscription Agreements with additional investors, pursuant to which it agreed to sell an additional 102,040 Shares of Common Stock (the "Additional Shares") and accompanying Common Stock Warrants (the "Additional Common Stock Warrants" and, together with the Additional Shares, the "Additional Securities") at the same price and on the same terms as the other Shares and Common Stock Warrants sold in the Common Stock Offering. The registration statement that the Company will file with the Securities and Exchange Commission covering the covering the resale of the Shares, the shares of Common Stock issuable upon exercise of the Common Stock Warrants, the shares of Common Stock underlying the CDIs issued in the CDI Offering, and the shares of Common Stock underlying the CDIs issuable upon exercise of the CDI Warrants will also cover the resale of the Additional Shares and the shares of Common Stock issuable upon exercise of the Additional Common Stock Warrants.

The Additional Securities were issued and sold without registration under the Securities Act, in reliance on the exemption provided by Section 4(a)(2) of the Securities Act, including under Rule 506 of Regulation D promulgated thereunder.

On October 27, 2025, the Company closed the Common Stock Offering (including, for the avoidance of doubt, with respect to the Additional Securities) and issued an aggregate of 2,346,936 Shares and Common Stock Warrants to purchase an aggregate of 2,346,936 shares of Common Stock. The Company received approximately US$11.5 million in gross proceeds from the Common Stock Offering.

#### Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

------

#### SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Anteris Technologies Global Corp.** | **Anteris Technologies Global Corp.** |
| Date: October 27, 2025 | By: | /s/ Wayne Paterson |
|  |  | Name: Wayne Paterson |
|  |  | Title: Vice Chairman and Chief Executive Officer |

---

------